2020
DOI: 10.3389/fphar.2019.01595
|View full text |Cite
|
Sign up to set email alerts
|

Dl-NBP (Dl-3-N-Butylphthalide) Treatment Promotes Neurological Functional Recovery Accompanied by the Upregulation of White Matter Integrity and HIF-1α/VEGF/Notch/Dll4 Expression

Abstract: Dl-3-n-butylphthalide (dl-NBP) was approved by the FDA of China for the treatment of acute ischemic stroke. Dl-NBP has been shown to promote neurological functional recovery and enhance white matter integrity using an endothelin-1-induced focal permanent cerebral ischemia model, which could mimic those patients who have no opportunity to receive either tissue plasminogen activator (tPA) thrombolysis or endovascular therapy. However, it is not clear whether dl-NBP could promote neurological functional recovery … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
16
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
5
2

Relationship

0
7

Authors

Journals

citations
Cited by 30 publications
(16 citation statements)
references
References 27 publications
0
16
0
Order By: Relevance
“…A synthetic compound with intrinsic anti-inflammatory, anti-oxidative, and anti-apoptotic properties approved for the treatment of stroke in China and currently in clinical trials in the United States. Li et al, 2019;Wang et al, 2019 Liraglutide/exenatide Glucagon-like peptide-1 agonists that reduce infarct size and improve neurological function in animals. Ongoing clinical trials.…”
Section: Di-3-n-butylphthalide (Nbp)mentioning
confidence: 99%
See 3 more Smart Citations
“…A synthetic compound with intrinsic anti-inflammatory, anti-oxidative, and anti-apoptotic properties approved for the treatment of stroke in China and currently in clinical trials in the United States. Li et al, 2019;Wang et al, 2019 Liraglutide/exenatide Glucagon-like peptide-1 agonists that reduce infarct size and improve neurological function in animals. Ongoing clinical trials.…”
Section: Di-3-n-butylphthalide (Nbp)mentioning
confidence: 99%
“…For pharmacologic neuroprotection, our understanding of the mechanisms of tissue damage following ischemic stroke has advanced, providing scientists with viable targets for neuroprotective therapeutics. Many developed and tested therapeutics have targeted the modulation of inflammation, oxidative stress, excitotoxicity, or apoptosis, all of which have been implicated in post-stroke tissue damage (Goenka et al, 2019;Wang et al, 2019). However, despite the relatively high levels of therapeutic benefits identified by these treatments in animal models, limited success has been observed in the clinic despite the hundreds of clinical trials run.…”
Section: Neuroprotectionmentioning
confidence: 99%
See 2 more Smart Citations
“…Dl-3-n-butylphthalide (D3NB) is a synthetic chiral compound originally isolated from the seeds of Apium graveolens and can cross the BBB (Li et al, 2019b , c ). D3NB was approved by the Food and Drug Administration of China for the treatment of ischemic stroke (Wang et al, 2019 ). Previous studies have indicated that D3NB has diverse neuroprotective effects in CCH, such as preserving white matter integrity (Han et al, 2019 ), regulating endoplasmic reticulum stress and the Shh/Ptch1 signaling-pathway (Niu et al, 2019 ), and promoting neovascularization (Xiong et al, 2017 ; Li et al, 2019c ).…”
Section: Introductionmentioning
confidence: 99%